A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease

Status:
Terminated

Trial end date:
2015-08-01

Target enrollment:

Participant gender:

The purpose of this study is to investigate the effect of the study medication (Eligard®) on cancer markers (in the blood) of prostate cancer.

Phase 4

Astellas Pharma Europe Ltd.

Leuprolide